Corbus Pharmaceuticals Holdings Inc CRBP announced that data from the first-in-human clinical study of CRB-701 (SYS6002) is being presented at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.
The Phase 1 dose escalation study is being conducted in China and is enrolling participants with metastatic urothelial cancer (mUC) as well as participants with other solid tumors prospectively confirmed to have nectin-4 positive tumors.
The study opened for enrollment in January 2023, and data through December 2023 from the first eighteen participants reflective of the first six dose cohorts (0.2-3.6mg/kg) will be shared.
Dose level 5 (2.7 mg/kg) and above represents the predicted therapeutically relevant doses based on allometric scaling.
A mixed tumor population (n=7) receiving doses of 2.7 mg/kg or 3.6 mg/kg demonstrated an ORR of 43% (3 partial responses -2 unconfirmed and one non-responding participant with no-nectin-4 expression) and a disease control rate of 71%.
The longest observed response to date is 11 cycles (~10 months) and ongoing.
Single-dose PK suggested that TAb, ADC, and MMAE increase in an approximate dose-proportional manner. No obvious accumulation was observed on cycle 3, day 1.
Compared to the exposures achieved with enfortumab vedotin (EV) at 1.25 mg/kg Q1W x21 days, CRB-701 (SYS6002) consistently demonstrated lower free MMAE concentrations.
CRB-701 was well-tolerated, with most adverse events being grade one or two and reversible. No adverse events above grade three were observed.
The dose escalation is ongoing at cohort 7 (4.5 mg/kg).
No cases of drug-related peripheral neuropathy or skin rash have been reported to date.
Price Action: CRBP shares are up 257.80% at $30.20 on the last check Friday.
Image by PDPics from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
